Home › Focal Segmental Glomerulosclerosis › California
Focal Segmental Glomerulosclerosis clinical trials in California
8 studies for Focal Segmental Glomerulosclerosis are looking for participants at sites in California.
Cities in California
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
- Investigator Site #2, Chula Vista
- Investigator Site #28, Garden Grove
- Investigator Site #14, Los Angeles
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07268638A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
- West Coast Kidney Institute, Fremont
- Kidney Disease Medical Group, Glendale
- Valiance Clinical Research, Huntington Park
- and 8 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 30, 2026 · NCT07220083A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
- University of California Irvine Medical Center- Site Number : 8400015, Orange
- University of California San Francisco - Parnassus Heights- Site Number : 8400012, San Francisco
RecruitingPhase 2
Ages 16 to 75 · All sexes · Updated Sep 23, 2026 · NCT06500702Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
- Loma Linda University Children's Hospital, Loma Linda
- Loma Linda University Hospital, Loma Linda
Recruiting
Up to age 75 · All sexes · Updated Aug 28, 2026 · NCT04065438Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- Loma Linda University Children's Hospital, Loma Linda
- Cedars Sinai Medical Center, Los Angeles
Recruiting
Up to age 21 · All sexes · Updated Aug 28, 2026 · NCT02235857Nephrotic Syndrome Study Network
- University of Southern California-Children's Hospital, Los Angeles
- Stanford University School of Medicine, Palo Alto
- University of California San Francisco Benioff Children's Hospitals, San Francisco
- and 1 more
RecruitingObservational study
Up to age 80 · All sexes · Updated Jun 10, 2026 · NCT01209000Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles, Los Angeles
- Kaiser Permanente, Oakland
- and 2 more
RecruitingPhase 3
Ages 12 to 80 · All sexes · Updated Feb 3, 2026 · NCT05183646From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.